Evaluating PEGASUS - a Group Intervention for Young People With an Autism Spectrum Disorder

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Institute of Child Health.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Institute of Child Health
ClinicalTrials.gov Identifier:
NCT01187940
First received: August 23, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted

August 23, 2010
August 23, 2010
September 2010
September 2012   (final data collection date for primary outcome measure)
  • Autism Knowledge Questionnaire [ Time Frame: 30 months ] [ Designated as safety issue: No ]
    All measures taken at baseline, termination of treatment and six months follow-up.
  • Child Behaviour Checklist [ Time Frame: 30 months ] [ Designated as safety issue: No ]
    All measures taken at baseline, termination of treatment and six months follow-up.
  • Vineland-II, Rosenburg Self-Esteem Scale [ Time Frame: 30 months ] [ Designated as safety issue: No ]
    All measures taken at baseline, termination of treatment and six months follow-up.
  • Parenting Stress index [ Time Frame: 30 months ] [ Designated as safety issue: No ]
    All measures taken at baseline, termination of treatment and six months follow-up.
Same as current
No Changes Posted
Qualitative interview conducted at baseline and termination. [ Time Frame: 30 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Evaluating PEGASUS - a Group Intervention for Young People With an Autism Spectrum Disorder
Evaluating Psychoeducation for People With Autism Spectrum Disorder

When a clinician gives an autism spectrum disorder (ASD) diagnosis they hope this will be helpful to the person receiving it and their family. In reality children with an ASD describe few benefits to receiving this diagnosis - they often report feeling confused and stigmatised by it. Parents can also struggle to understand their child's diagnosis and report needing greater support from professionals in this respect (Midence & O'neill, 1999; Osborne & Reed, 2008).

Little is known about how to help children and families integrate their ASC 'label' in a positive way. Whilst there is anecdotal evidence that psychoeducation after diagnosis can help, there has been no formal evaluation of this approach and no evidence-based programmes of this type are available. In the current study the investigators aim to test empirically a psychoeducational programme for children with an ASD ('PEGASUS'), using a randomised controlled design. The investigators aim to evaluate whether this psychological and educational intervention impacts positively upon understanding of ASC, self-esteem, functional adaption, well-being and family functioning.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Efficacy of PEGASUS
Behavioral: PEGASUS
PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
  • Experimental: PEGASUS
    PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
    Intervention: Behavioral: PEGASUS
  • No Intervention: Placebo
    Will receive managment as usual from their local educational and NHS services
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
40
Not Provided
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Received an ASD diagnosis from Child and Adolescent Psychiatrist, Clinical Psychologist or Paediatrician.
  2. Aware of ASD diagnosis.
  3. Aged between 9 and 14 years.
  4. Able to function in group setting, as evidenced in educational context.
  5. Speaks English

Exclusion Criteria:

  1. No generalised Intellectual Disability as indicated by IQ below 65.
  2. Not engaged in additional formal psychosocial intervention during study period.
  3. Not taking psychiatric medication at baseline assessment, or taking a stable dose of psychiatric medication expected to remain constant throughout study participation.
Both
9 Years to 14 Years
No
Contact: William Mandy, Dr w.mandy@ucl.ac.uk
United Kingdom
 
NCT01187940
09BS22
No
Research Governance Co-ordinator, Institute of Child Health
Institute of Child Health
Not Provided
Study Director: William Mandy, Dr Institute of Child Health
Principal Investigator: David Skuse, Professor Institute of Child Health
Institute of Child Health
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP